Literature DB >> 29859324

Treadmill exercise attenuates the severity of physical dependence, anxiety, depressive-like behavior and voluntary morphine consumption in morphine withdrawn rats receiving methadone maintenance treatment.

Maryam Alizadeh1, Mahdi Zahedi-Khorasani2, Hossein Miladi-Gorji3.   

Abstract

This study was designed to examine whether treadmill exercise would attenuate the severity of physical dependence, methadone-induced anxiety, depression and voluntary morphine consumption in morphine withdrawn rats receiving methadone maintenance treatment (MMT). The rats were chronically treated with bi-daily doses (10 mg/kg, at 12 h intervals) of morphine for 14 days. The exercising rats receiving MMT were forced to run on a motorized treadmill for 30 days during morphine withdrawal. Then, rats were tested for the severity of morphine dependence, the elevated plus-maze (EPM), sucrose preference test (SPT) and voluntary morphine consumption using a two-bottle choice (TBC) paradigm. The results showed that naloxone- precipitated opioid withdrawal signs were decreased in exercising morphine-dependent rats receiving MMT than sedentary rats. Also, the exercising morphine-dependent rats receiving MMT exhibited an increased time on open arms, preference for sucrose and a lower morphine preference ratio than sedentary rats. We conclude that treadmill exercise decreased the severity of physical dependence, anxiety/depressive-like behaviors and also the voluntary morphine consumption in morphine withdrawn rats receiving MMT. Thus, exercise may benefit in the treatment of addicts during MMT.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anxiety; Depression; Exercise; Methadone; Morphine; Morphine preference

Mesh:

Substances:

Year:  2018        PMID: 29859324     DOI: 10.1016/j.neulet.2018.05.044

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

Review 1.  Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.

Authors:  George F Koob
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

Review 2.  Aerobic exercise as a promising nonpharmacological therapy for the treatment of substance use disorders.

Authors:  Gigliola Marrero-Cristobal; Ursula Gelpi-Dominguez; Roberto Morales-Silva; John Alvarado-Torres; Joshua Perez-Torres; Yobet Perez-Perez; Marian Sepulveda-Orengo
Journal:  J Neurosci Res       Date:  2021-12-01       Impact factor: 4.433

Review 3.  The Opioid-Addicted Tetrapartite Synapse.

Authors:  Anna Kruyer; Vivian C Chioma; Peter W Kalivas
Journal:  Biol Psychiatry       Date:  2019-06-13       Impact factor: 13.382

4.  Effects of voluntary exercise and sex on multiply-triggered heroin reinstatement in male and female rats.

Authors:  J R Smethells; A Greer; B Dougen; M E Carroll
Journal:  Psychopharmacology (Berl)       Date:  2019-11-11       Impact factor: 4.530

5.  Use of home cage wheel running to assess the behavioural effects of administering a mu/delta opioid receptor heterodimer antagonist for spontaneous morphine withdrawal in the rat.

Authors:  Michael M Morgan; Danielle L Peecher; John M Streicher
Journal:  Behav Brain Res       Date:  2020-10-06       Impact factor: 3.332

Review 6.  Aerobic Exercise Interventions for Patients in Opioid Maintenance Treatment: A Systematic Review.

Authors:  Danielle E Jake-Schoffman; Meredith S Berry; Marissa L Donahue; Demetra D Christou; Jesse Dallery; Jillian M Rung
Journal:  Subst Abuse       Date:  2020-06-11

7.  Environmental Enrichment Ameliorates Psychological Dependence Symptoms and Voluntary Morphine Consumption in Morphine Withdrawn Rats Under Methadone Maintenance Treatment.

Authors:  Marjan Lari; Hossein Miladi-Gorji; Mahmoud Najafi; Ali-Mohammad Rezaei
Journal:  Basic Clin Neurosci       Date:  2021-09-01

8.  Comparative benefits of social housing and buprenorphine on wheel running depressed by morphine withdrawal in rats.

Authors:  Jonah D Stickney; Michael M Morgan
Journal:  Psychopharmacology (Berl)       Date:  2021-07-10       Impact factor: 4.530

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.